236 related articles for article (PubMed ID: 31469421)
1. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Offin M; Feldman D; Ni A; Myers ML; Lai WV; Pentsova E; Boire A; Daras M; Jordan EJ; Solit DB; Arcila ME; Jones DR; Isbell JM; Beal K; Young RJ; Rudin CM; Riely GJ; Drilon A; Tabar V; DeAngelis LM; Yu HA; Kris MG; Li BT
Cancer; 2019 Dec; 125(24):4380-4387. PubMed ID: 31469421
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
[TBL] [Abstract][Full Text] [Related]
3. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
4. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
5. EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.
Tomasini P; Serdjebi C; Khobta N; Metellus P; Ouafik L; Nanni I; Greillier L; Loundou A; Fina F; Mascaux C; Barlesi F
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999344
[TBL] [Abstract][Full Text] [Related]
6. Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
Wang TJ; Saad S; Qureshi YH; Jani A; Nanda T; Yaeh AM; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Lesser J; Halmos B; Stoopler MB; Lassman AB; Cheng SK; Isaacson SR
Neuro Oncol; 2015 Jul; 17(7):1022-8. PubMed ID: 25910841
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
[TBL] [Abstract][Full Text] [Related]
10. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
[TBL] [Abstract][Full Text] [Related]
11. Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Saruwatari K; Ikeda T; Saeki S; Shingu N; Imamura K; Komatu T; Ushijima S; Maruyama H; Kashiwabara K; Tomita Y; Ichiyasu H; Fujii K; Sakagami T
Anticancer Res; 2019 Feb; 39(2):923-931. PubMed ID: 30711977
[TBL] [Abstract][Full Text] [Related]
12. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
13. Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.
Hsu F; Nichol A; Toriumi T; De Caluwe A
Acta Oncol; 2017 Sep; 56(9):1175-1180. PubMed ID: 28521651
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
15. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
16. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers.
Eng J; Hsu M; Chaft JE; Kris MG; Arcila ME; Li BT
Lung Cancer; 2016 Sep; 99():53-6. PubMed ID: 27565914
[TBL] [Abstract][Full Text] [Related]
18. CT features of HER2-mutant lung adenocarcinomas.
Sawan P; Plodkowski AJ; Li AE; Li BT; Drilon A; Capanu M; Ginsberg MS
Clin Imaging; 2018; 51():279-283. PubMed ID: 29906786
[TBL] [Abstract][Full Text] [Related]
19. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
